Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment

Fig. 2

PTC-209 impairs myeloma cell viability and proliferation. a PTC-209 downregulated BMI-1 protein levels in all MM cell lines analysed by intracellular staining using flow cytometry. Histograms are representative for three independent experiments. b Reduced viability 96 h post treatment was observed in all MM cell lines in a dose-dependent manner, but not in BMSCs or PBMCs (c). d Downregulation of CCND1 and MYC as well as upregulation of CDNK1A and CDKN1B was noted 5 h post treatment. e Deregulation of proliferation-associated genes translated into a significant increase of cells in the G1 phase and concurrent decrease in the S and G2M phase of the cell cycle 24 h post treatment. ***P < 0.001, **P < 0.01 and *P < 0.05 vs DMSO control

Back to article page